Premium
The use of statistical methodology to determine the accuracy of grading within a diabetic retinopathy screening programme
Author(s) -
Oke J. L.,
Stratton I. M.,
Aldington S. J.,
Stevens R. J.,
Scanlon P. H.
Publication year - 2016
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.13053
Subject(s) - medicine , interquartile range , retinopathy , diabetic retinopathy , grading (engineering) , diabetes mellitus , ophthalmology , optometry , civil engineering , engineering , endocrinology
Aims We aimed to use longitudinal data from an established screening programme with good quality assurance and quality control procedures and a stable well‐trained workforce to determine the accuracy of grading in diabetic retinopathy screening. Methods We used a continuous time‐hidden Markov model with five states to estimate the probability of true progression or regression of retinopathy and the conditional probability of an observed grade given the true grade (misclassification). The true stage of retinopathy was modelled as a function of the duration of diabetes and HbA 1c . Results The modelling dataset consisted of 65 839 grades from 14 187 people. The median number [interquartile range ( IQR )] of examinations was 5 (3, 6) and the median ( IQR ) interval between examinations was 1.04 (0.99, 1.17) years. In total, 14 227 grades (21.6%) were estimated as being misclassified, 10 592 (16.1%) represented over‐grading and 3635 (5.5%) represented under‐grading. There were 1935 (2.9%) misclassified referrals, 1305 were false‐positive results (2.2%) and 630 were false‐negative results (11.0%). Misclassification of background diabetic retinopathy as no detectable retinopathy was common (3.4% of all grades) but rarely preceded referable maculopathy or retinopathy. Conclusion Misclassification between lower grades of retinopathy is not uncommon but is unlikely to lead to significant delays in referring people for sight‐threatening retinopathy.